| Wnt/β-catenin signaling: the culprit in pancreatic carcinogenesis and therapeutic resistance M Ram Makena, H Gatla, D Verlekar, S Sukhavasi, M K. Pandey, ... International journal of molecular sciences 20 (17), 4242, 2019 | 128 | 2019 |
| Advancement of NF-κB signaling pathway: a novel target in pancreatic cancer KC Pramanik, MR Makena, K Bhowmick, MK Pandey International journal of molecular sciences 19 (12), 3890, 2018 | 125 | 2018 |
| Crizotinib synergizes with chemotherapy in preclinical models of neuroblastoma K Krytska, HT Ryles, R Sano, P Raman, NR Infarinato, TD Hansel, ... Clinical Cancer Research 22 (4), 948-960, 2016 | 115 | 2016 |
| Cancer stem cells: Road to therapeutic resistance and strategies to overcome resistance MR Makena, A Ranjan, V Thirumala, AP Reddy Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1866 (4), 165339, 2020 | 106 | 2020 |
| Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression MH Kang, J Wang, MR Makena, JS Lee, N Paz, CP Hall, MM Song, ... Clinical Cancer Research 21 (5), 1139-1150, 2015 | 102 | 2015 |
| Regulation of chemokines and cytokines by histone deacetylases and an update on histone decetylase inhibitors in human diseases HR Gatla, N Muniraj, P Thevkar, S Yavvari, S Sukhavasi, MR Makena International journal of molecular sciences 20 (5), 1110, 2019 | 89 | 2019 |
| Subtype specific targeting of calcium signaling in breast cancer MR Makena, R Rao Cell calcium 85, 102109, 2020 | 46 | 2020 |
| ALT neuroblastoma chemoresistance due to telomere dysfunction–induced ATM activation is reversible with ATM inhibitor AZD0156 B Koneru, A Farooqi, TH Nguyen, WH Chen, A Hindle, C Eslinger, ... Science translational medicine 13 (607), eabd5750, 2021 | 40 | 2021 |
| Reactive oxygen species–mediated synergism of fenretinide and romidepsin in preclinical models of T-cell lymphoid malignancies MR Makena, B Koneru, TH Nguyen, MH Kang, CP Reynolds Molecular cancer therapeutics 16 (4), 649-661, 2017 | 37 | 2017 |
| A Ca2+-ATPase Regulates E-cadherin Biogenesis and Epithelial–Mesenchymal Transition in Breast Cancer Cells DK Dang, MR Makena, JP Llongueras, H Prasad, M Ko, M Bandral, ... Molecular Cancer Research 17 (8), 1735-1747, 2019 | 35 | 2019 |
| MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma SJ Wei, TH Nguyen, IH Yang, DG Mook, MR Makena, D Verlekar, ... Cell death & disease 11 (5), 368, 2020 | 23 | 2020 |
| Fenretinide via NOXA induction, enhanced activity of the BCL-2 inhibitor venetoclax in high BCL-2–expressing neuroblastoma preclinical models TH Nguyen, B Koneru, SJ Wei, WH Chen, MR Makena, E Urias, MH Kang, ... Molecular cancer therapeutics 18 (12), 2270-2282, 2019 | 18 | 2019 |
| Large population analysis of secondary cancers in pediatric leukemia survivors S Yavvari, Y Makena, S Sukhavasi, MR Makena Children 6 (12), 130, 2019 | 16 | 2019 |
| Cytotoxicity and molecular activity of fenretinide and metabolites in T-cell lymphoid malignancy, neuroblastoma, and ovarian cancer cell lines in physiological hypoxia MM Song, MR Makena, A Hindle, B Koneru, TH Nguyen, DU Verlekar, ... Anti-Cancer Drugs 30 (2), 117-127, 2019 | 13 | 2019 |
| Vorinostat and fenretinide synergize in preclinical models of T-cell lymphoid malignancies MR Makena, TH Nguyen, B Koneru, A Hindle, WH Chen, DU Verlekar, ... Anti-Cancer Drugs 32 (1), 34-43, 2020 | 11* | 2020 |
| Secretory pathway Ca2+-ATPase SPCA2 regulates mitochondrial respiration and DNA damage response through store-independent calcium entry MR Makena, M Ko, AX Mekile, N Senoo, DK Dang, J Warrington, ... Redox biology 50, 102240, 2022 | 10 | 2022 |
| Epigenetic modulation of SPCA2 reverses epithelial to mesenchymal transition in breast cancer cells MR Makena, M Ko, DK Dang, R Rao Cancers 13 (2), 259, 2021 | 9 | 2021 |
| Rethinking oncologic treatment strategies with interleukin-2 B Ko, N Takebe, O Andrews, MR Makena, AP Chen Cells 12 (9), 1316, 2023 | 6 | 2023 |
| The O6-methyguanine-DNA methyltransferase inhibitor O6-benzylguanine enhanced activity of temozolomide+ irinotecan against models of high-risk neuroblastoma A Hindle, B Koneru, MR Makena, L Lopez-Barcons, WH Chen, ... Anti-cancer drugs 32 (3), 233-247, 2021 | 6 | 2021 |
| Cytotoxic activity of difluoromethylornithine compared with fenretinide in neuroblastoma cell lines MR Makena, HE Cho, TH Nguyen, B Koneru, DU Verlekar, A Hindle, ... Pediatric blood & cancer 65 (12), e27447, 2018 | 6 | 2018 |
C Patrick ReynoldsCancer Center Director, TTUHSC School of Medicine在 ttuhsc.edu 的电子邮件经过验证
